Molecule Bioavailability · Research briefing

Why 15% Unencapsulated Azelaic Acid Stings—And How Lipid Bilayer Entrapment Solves Stratum Corneum Irritation

Azelaic acid works on acne, rosacea and melasma, but burning and stinging stop many patients from continuing. This briefing explains where the sting comes from and how vesicle entrapment changes what nerve endings feel.

Answer first

Azelaic acid stings because a 15–20% dicarboxylic acid load meets the skin all at once, raising local acidity and stimulating nerve endings, especially where the barrier is already compromised. Entrapping the acid in lipid nanovesicles lowers the free fraction at the surface and releases it gradually. The aim is the same total dose with a smaller, slower peak.

A good molecule with a tolerability problem

Azelaic acid is a naturally occurring C9 dicarboxylic acid with a broad profile. It is antibacterial against Cutibacterium acnes, normalises keratinisation, and competitively inhibits tyrosinase, which is why it is used in acne, papulopustular rosacea and hyperpigmentation.[1] A 2023 systematic review found it more effective than vehicle across acne, rosacea and melasma.[2]

The weak point is tolerability. Burning, stinging, itching and tingling on application have been reported since the earliest clinical reviews.[1] They are usually mild and transient, but they come at the worst possible moment: the first weeks, when a patient is deciding whether to continue.

Where the sting comes from

Three factors combine.

  1. Concentration. Clinical efficacy needs 15–20%. Azelaic acid is only modestly soluble in water, so many vehicles carry it as a suspended or partly dissolved acid that meets the skin as a high local load.
  2. Acidity at the surface. Free carboxylic acid groups lower the pH of the film on the skin, and acid-sensing nerve endings respond to that.
  3. A compromised barrier. In rosacea and acne-prone skin the stratum corneum's lipid organisation is often disturbed. A healthy barrier depends on ordered ceramide, cholesterol and free-fatty-acid lamellae,[3] and when they are disordered, small molecules and protons reach nerve-rich viable tissue faster.

At 188 Da azelaic acid is well under the 500 Da threshold,[4] so getting it into skin is not the problem. The problem is that too much of it arrives at once.

What lipid bilayer entrapment changes

Encapsulation does not make azelaic acid stronger. It changes when and how the acid meets tissue.

  • A lower free fraction. Part of the dose sits inside the vesicle, associated with the lipid lamellae and the polar mantle, rather than dissolved in the surface film.
  • Phased release. Cetosomes move through the stratum corneum and then break into smaller penetration units, so the cargo is released progressively rather than as one bolus.[5]
  • Barrier-compatible chemistry. Cetylated esters and fatty alcohols are lipid-like and lamellar. Unlike solvent-based penetration enhancers, they do not work by stripping or fluidising barrier lipids, and the patent describes delivery without permanent disruption of barrier function.[5]

The concentration–time profile changes as a result. A conventional vehicle produces a sharp early peak that crosses the irritation threshold. A vesicle reservoir gives a flatter, longer exposure that stays within the effective range.

What the cetosome vehicle literature shows

No published trial yet compares cetosomal and conventional azelaic acid head to head. The closest controlled data for the cetosome vehicle itself come from topical minoxidil, where the comparator was a conventional ethanol and propylene glycol solution. In a randomised, open-label study, 9% of patients on the cetosomal formulation reported adverse events (pruritus, flaking, rash) versus 41% on the alcohol-based solution (p = 0.02).[6] The active, the condition and the comparator vehicle are all different, so this is an indication of vehicle tolerability, not a result that transfers to azelaic acid.

Practical implications

  • When patients stop azelaic acid because of stinging, the vehicle may be failing them, not the molecule.
  • Encapsulated formulations are the logical next step for patients with sensitive or rosacea-prone skin who have not tolerated conventional 15–20% gels or creams.
  • Barrier support (ceramide-dominant moisturisers, avoiding alcohol-based toners) still helps, whatever the vehicle.

Limitations

Tolerability gains from encapsulation are mechanistically well grounded, but for azelaic acid specifically they have not been quantified in randomised trials. Rosacea flares have many triggers, so stinging can come from the condition as well as the product. Persistent or severe reactions should be reviewed by a dermatologist.

Frequently asked

Why does azelaic acid burn when I apply it?

Prescription azelaic acid is used at 15–20%. When that much free acid contacts skin, especially skin with an impaired barrier such as in rosacea, it causes transient burning, stinging and itching. These are the most commonly reported side effects and usually fade over the first weeks.

Does encapsulated azelaic acid sting less?

The rationale is strong. Entrapment lowers the free acid at the surface and spreads release over time, which reduces the peak exposure linked to stinging. Head-to-head trials of encapsulated versus conventional azelaic acid are still needed to measure the size of the benefit.

Is encapsulated azelaic acid less effective?

Encapsulation does not change how azelaic acid works. Its antibacterial, anti-keratinising and anti-tyrosinase actions stay the same. The goal is better tolerability and adherence, which in practice often decide whether a treatment works for a patient.


References

  1. Fitton A, Goa KL. Azelaic Acid: A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 41(5):780–798. 1991.DOI 10.2165/00003495-199141050-00007
  2. King S, Campbell J, Rowe R, et al. A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging. Journal of Cosmetic Dermatology 22(10):2650–2662. 2023.DOI 10.1111/jocd.15923
  3. Elias PM. Stratum Corneum Defensive Functions: An Integrated View. Journal of Investigative Dermatology 125(2):183–200. 2005.DOI 10.1111/j.0022-202X.2005.23668.x
  4. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 9(3):165–169. 2000.DOI 10.1034/j.1600-0625.2000.009003165.x
  5. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
  6. Sattur S, Talathi A, Shetty G, Arsiwala S, Pereira R, Dhoot D. Comparative Clinical Study Evaluating the Efficacy and Safety of Topical 5% Cetosomal Minoxidil and Topical 5% Alcohol-Based Minoxidil Solutions for the Treatment of Androgenetic Alopecia in Indian Men. Cureus 15(10):e46568. 2023.DOI 10.7759/cureus.46568 · PMID 37937040 · PMC10626207Randomised, open-label, 5 centres; 80 enrolled, 40 analysed. One author employed by the product's marketing company.

Methodology

Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.

Conflict of interest & scope

Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.